Fevertree Drinks Share Discussion Threads

[yf23_1] 02/12/2018 12:30

Its still spikey on the candles, needs to break £25 for an attempt at an up-wave, IMO.

[skinny] 02/12/2018 11:48

A mention .

[christh] 01/12/2018 21:16

Villarich
the dodgiest person I came across.
Weirdo,nasty character.
pally with him, he will stab you in the back.

Beware!
He is following Bullocks ki!!!!!
...and you might get infected!

[villarich] 01/12/2018 21:13

Haha top stuff mate. All the best

[villarich] 01/12/2018 21:13

Of course he didn't

[christh] 01/12/2018 20:50

Top mutual fund holders
Holder..............................Shares.....Date reported..% out...Value
Fidelity Growth Company Fund.......1,780,147..30 Jun 2018...1.54%....6,036,478,477
Artisan Global Opportunities Fund..1,560,017..31 Dec 2017...1.35%....3,486,637,995
Fidelity Advisor New Insights Fund.1,183,305..30 Jun 2018...1.02%....4,012,587,255
Morgan Stanley Inst Fd Inc-Global Opportunity Port.1,051,352..31 Dec 2017.0.91% .....2,349,771,720
College Retirement Equities Fund-Global Equities Account...861,174..31 Mar 2018...0.75%.....2,368,228,500
Fidelity Mid-Cap Stock Fund......801,022....30 Jun 2018...0.69%..2,716,265,602
Oberweis International Opportunities Fund.....767,760...30 Jun 2018
..0.66%....2,603,474,160
Morgan Stanley Inst Fd Inc-International Opportunity Port...606,908...31 Dec 2017....0.53%....1,356,439,380
College Retirement Equities Fund-Stock Account...592,392...31 Dec 2017....0.51%....1,323,996,120
TIAA-CREF Funds-International Opportunities Fund...543,423..31 Jan 2018..0.47%...1,347,145,617

[bulltradept] 01/12/2018 20:39

Villarich,

"Bull you bad man! How DARE you besmirch the good name of Christh’s fair maiden Fever Tree. He will smite you in this life and the next."

My bad. I should have learnt my lesson when you initially stated it would be an up hill task so to speak. Hey ho, but I have learnt my lesson now!

[christh] 01/12/2018 20:18

1st December 2018 06:56
FEVR bubbled higher after resilient British soft drink industry data from Nielsen showed the company’s sales rising by 31.8% in the 4 weeks to early November, down from the 37% growth reported in the previous 2 months but a relief to investors who had been wondering why the posh tonic maker hadn’t released a trading update since July.

Morgan Stanley and Jefferies both issued “buy” recommendations, suggesting that the company’s share price weakness represented a good opportunity.

[christh] 01/12/2018 20:03

Fevertree (FEVR) has the US firmly in its sights.

The group has signed a deal with Southern Glazer's Wine and Spirits – the largest North American distributor of its kind –to be the company’s exclusive distribution partner in bars and restaurants across 29 states.
Chief executive Tim Warrillow says this will allow for national campaigns across the US, which should improve Fevertree's brand awareness across the pond.

But it already appears to be proving popular with Americans: US sales rose 15% to £15.1m during the first half alone.

Rest assured, US expansion hasn't come at the expense of the domestic business. Fevertree is still the number one mixer brand sold in the UK off-trade market, helping to take UK sales up 73% to £58m. The “Refreshingly Light” range of lower-sugar mixers have also been rolled out ahead of the incoming sugar tax.

Analysts at Investec expect pre-tax profits of £67.8m in 2018, giving EPS of 46.8p, compared with £57.1m and 39.7p in 2017.

[christh] 01/12/2018 19:58

Blue-chip analysts tell investors to plough into Fevertree after recent sell-off
13:11 30 Nov 2018
Jefferies still has its uber-bullish 4,300p price target in place, despite a sell-off, which has seen shares almost halve over the past three months
fevertree drink
Fevertree’s rapid growth in its home UK market is beginning to normalise

Fevertree Drinks PLC (LON:FEVR) shares perked up on Friday after analysts at two major investment banks published bullish research notes, soothing investors who have had to nurse chunky losses in recent weeks.

The posh tonic maker was noticeably silent in November, a month when investors have become used to seeing a trading update telling them that full-year results will be well ahead of forecasts.


That, coupled with the wider equities sell-off, which has rocked stock markets of late, has seen Fevertree shares plunge from almost 4,000p in September to 2,400p now, wiping out all of 2018’s gains.

Morgan Stanley analyst Richard Felton reckons there is “still plenty of scope” for results to come in ahead of forecasts though.

Jefferies’ Ed Mundy also remains a fan and thinks the recent slump “offers an entry point into one of the most attractive growth stories in European beverages”, noting that management’s tone remains “confidentR21;.

According to data from consumer insights group Nielsen, Fevertree’s growth has been slowing in recent months, although given the rapid growth seen over the past few years, Munday says a normalisation of growth “was always expected”.

His calculations suggest sales of Fevertree Drinks in the UK – which accounts for half of all revenue – could grow by up to 40-50% in the second half of this year.

The US will take over the reins as the AIM company’s growth driver over the next year or two and Mundy highlights the “good conditions” currently in place across the pond for Fevertree to enjoy a successful Stateside expansion.

The analyst repeated his blockbuster 4,300p price target and ‘buy’ recommendation.

Fevertree shares added 2.4% in early afternoon trading to 2,397p, still some way off September’s highs.

www.proactiveinvestors.co.uk/companies/news/210309/blue-chip-analysts-tell-investors-to-plough-into-fevertree-after-recent-sell-off-210309.html

[traderglt] 01/12/2018 19:43

Chris you did see - slow down in growth - in that story didn't you

[villarich] 01/12/2018 18:29

Bull you bad man! How DARE you besmirch the good name of Christh's fair maiden Fever Tree. He will smite you in this life and the next.

[christh] 01/12/2018 17:53

30 November Friday 15:00 GMT

● Fevertree Drinks bounced in response to positive UK soft drink industry data, which eased concerns stemming from a lack of trading updates from the tonic water maker since July. The UK accounts for more than half of revenues for Fevertree, which had released a November trading statement each year since flotation in 2014.

Nielsen’s survey showed Fevertree sales up 31.8% for the four weeks to early November — a slowdown from the 37% growth reported in the previous two months, but still resilient in the face of heavy promotion for Schweppes and Suntory’s recently launched Merchant’s Heart brand.

Morgan Stanley and Jefferies both advised clients to use Fevertree’s recent weakness as an opportunity to buy.

[christh] 01/12/2018 17:49

30 friday 30 November 15:00 GMT

● Fevertree Drinks bounced in response to positive UK soft drink industry data, which eased concerns stemming from a lack of trading updates from the tonic water maker since July. The UK accounts for more than half of revenues for Fevertree, which had released a November trading statement each year since flotation in 2014.

Nielsen’s survey showed Fevertree sales up 31.8 per cent for the four weeks to early November — a slowdown from the 37 per cent growth reported in the previous two months, but still resilient in the face of heavy promotion for Schweppes and Suntory’s recently launched Merchant’s Heart brand.

Morgan Stanley and Jefferies both advised clients to use Fevertree’s recent weakness as an opportunity to buy.

from the FT

www.ft.com

[bulltradept] 01/12/2018 17:43

Christh,


The point of the whole article is about how the working capital of companies does and can change, the article is actually more about a FTSE 100 company as well as another, it is NOT a detrimental article about FEVR. The author just gives an example as to what may / could happen at some stage.

As I stated before, perhaps you are too emotionally and positionally (if there is such a word), involved in FEVR?

It wasn't any surprise that you would be the first to respond!

[christh] 01/12/2018 17:21

that's why the stupid person who wrote the article never mention the US growth that is expected to grow to 30%-35% this year.

Is he ignorant or he is deliberately omitted it?

read the article above and take a hint from the analyst!

He is saying BUY and price target £43.

[bulltradept] 01/12/2018 17:01

In this week's IC FEVR'S working capital position is highlighted:


Working capital warning signs: Why Fevertree concerns me

"I am always wary of companies where trade receivables are a high proportion of sales and even more so if the ratio is increasing.

Fevertree Drinks (FEVR) has many fans and has been one of the most profitable and fastest growing companies on the London market in recent years. I have mentioned this before in previous articles, but its growing trade receivables position as a percentage of sales/revenues over the past few years does concern me a little bit. It has seen increasing amounts of cash flow out of the business.

It might not be a problem and just be a reflection of Britain’s booming gin market, but could Fevertree’s rapid growth be partly explained by a higher proportion of its sales being due to more generous credit terms?

If it is, then how long can this continue? Fevertree’s sales growth rate will undoubtedly slow down as the company gets bigger, but if its sales growth in the UK weakened considerably and faster than is currently expected I would not be completely surprised."

There is much more to this article but I have only posted the bit concerning FEVR.

Cheers.

[christh] 01/12/2018 15:54

Blue-chip analysts tell investors to plough into Fevertree after recent sell-off
13:11 30 Nov 2018
Jefferies still has its uber-bullish 4,300p price target in place, despite a sell-off, which has seen shares almost halve over the past three months
fevertree drink
Fevertree’s rapid growth in its home UK market is beginning to normalise

Fevertree Drinks PLC (LON:FEVR) shares perked up on Friday after analysts at two major investment banks published bullish research notes, soothing investors who have had to nurse chunky losses in recent weeks.

The posh tonic maker was noticeably silent in November, a month when investors have become used to seeing a trading update telling them that full-year results will be well ahead of forecasts.


That, coupled with the wider equities sell-off, which has rocked stock markets of late, has seen Fevertree shares plunge from almost 4,000p in September to 2,400p now, wiping out all of 2018’s gains.

Morgan Stanley analyst Richard Felton reckons there is “still plenty of scope” for results to come in ahead of forecasts though.

Jefferies’ Ed Mundy also remains a fan and thinks the recent slump “offers an entry point into one of the most attractive growth stories in European beverages”, noting that management’s tone remains “confidentR21;.

According to data from consumer insights group Nielsen, Fevertree’s growth has been slowing in recent months, although given the rapid growth seen over the past few years, Munday says a normalisation of growth “was always expected”.

His calculations suggest sales of Fevertree Drinks in the UK – which accounts for half of all revenue – could grow by up to 40-50% in the second half of this year.

The US will take over the reins as the AIM company’s growth driver over the next year or two and Mundy highlights the “good conditions” currently in place across the pond for Fevertree to enjoy a successful Stateside expansion.

The analyst repeated his blockbuster 4,300p price target and ‘buy’ recommendation.

Fevertree shares added 2.4% in early afternoon trading to 2,397p, still some way off September’s highs.

www.proactiveinvestors.co.uk/companies/news/210309/blue-chip-analysts-tell-investors-to-plough-

[christh] 01/12/2018 15:52

Blue-chip analysts tell investors to plough into Fevertree after recent sell-off
13:11 30 Nov 2018
Jefferies still has its uber-bullish 4,300p price target in place, despite a sell-off, which has seen shares almost halve over the past three months
fevertree drink
Fevertree’s rapid growth in its home UK market is beginning to normalise

Fevertree Drinks PLC (LON:FEVR) shares perked up on Friday after analysts at two major investment banks published bullish research notes, soothing investors who have had to nurse chunky losses in recent weeks.

The posh tonic maker was noticeably silent in November, a month when investors have become used to seeing a trading update telling them that full-year results will be well ahead of forecasts.


That, coupled with the wider equities sell-off, which has rocked stock markets of late, has seen Fevertree shares plunge from almost 4,000p in September to 2,400p now, wiping out all of 2018’s gains.

Morgan Stanley analyst Richard Felton reckons there is “still plenty of scope” for results to come in ahead of forecasts though.

Jefferies’ Ed Mundy also remains a fan and thinks the recent slump “offers an entry point into one of the most attractive growth stories in European beverages”, noting that management’s tone remains “confidentR21;.

According to data from consumer insights group Nielsen, Fevertree’s growth has been slowing in recent months, although given the rapid growth seen over the past few years, Munday says a normalisation of growth “was always expected”.

His calculations suggest sales of Fevertree Drinks in the UK – which accounts for half of all revenue – could grow by up to 40-50% in the second half of this year.

The US will take over the reins as the AIM company’s growth driver over the next year or two and Mundy highlights the “good conditions” currently in place across the pond for Fevertree to enjoy a successful Stateside expansion.

The analyst repeated his blockbuster 4,300p price target and ‘buy’ recommendation.

Fevertree shares added 2.4% in early afternoon trading to 2,397p, still some way off September’s highs.

www.proactiveinvestors.co.uk/companies/news/210309/blue-chip-analysts-tell-investors-to-plough-into-fevertree-after-recent-sell-off-210309.html

[sogoesit] 01/12/2018 10:18

Pre-results TU next month.

I think we will see only half a year's effect of US organisation changes since the management changes only came into being on 1 June. So, imv, we will need to wait 'til March '19 for the real numbers (EPS) for FY2018 and then later in the year to see if growth has been entrenched in the US.
Patience is probably the watch word but then again markets are probably not going to help in calming every one down. Some reactions are non-sensical too, throwing-up yields in excess of 10% now, so it shouldn't be long before folks looking for bargains get going. I have started but may be early.

However, some of my growth stocks have lost over 50% from their highs and we're at -45% approx peak to trough with FEVR (-39% on closes).
If that should happen here, down 50%, we would be into the the 2000-2050 area.

But, on fundamentals I still think 60p EPS is achievable with a chance of upside making it reasonable value here (for a growth stock).

[villarich] 01/12/2018 09:57

Nice little price rise today. Back to £30 before we know it ;-)

[yf23_1] 30/11/2018 17:13

Its still spikey on the candles, needs to break £25 for an attempt at an up-wave, IMO.

[soundbuy] 30/11/2018 12:01

And Jefferies today

Nielsen data for four weeks to 4/11/18 shows FEVR growth +31.8% vs previous month +37.4%. If this level of growth continues, 2H UK growth will likely be +40%-50% (vs Jef +20%) after 1H +73%, providing c.8% upside risk to our top-line estimates.

................

Although Fever-Tree has not published a “unscheduled trading update” as many had expected, the company's tone remains confident. The company is still growing ahead of the category and a normalization of growth was always expected. H2 run rate robust, 31% growth for a category leader in the UK is still very positive and in absolute terms sales are growing on a monthly basis. Merchant heart is still very small, all other brands (excl. Schweppes and own label) account for c.4% of category.